Skip to main content

Catalyst Calendar

Scope

Mon, Sep 14, 2026

1 updates
NBTX
2:00 AM

NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer

All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasible One-year locoregional control rate was 79%, one-year local progression-free survival

Presentation / Abstract • Phase 1WCLC presentation Mon, Sep 14, 2026, EDTnanobiotix.com

Wed, Sep 9, 2026

1 updates

Tue, Aug 25, 2026

1 updates
NBTX
4:15 PM

Voting Rights and Shares Capital of the Company

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code:

nanobiotix.com

Thu, Jul 30, 2026

1 updates
NBTX
4:15 PM

Voting Rights and Shares Capital of the Company

PARIS, July 30, 2026 (GLOBE NEWSWIRE) -- In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) Paris, France, July 30, 2026 Market: Euronext Paris / Nasdaq Euronext

nanobiotix.com